- Record: found
- Abstract: not found
- Article: not found
Intravenous arketamine for treatment-resistant depression: open-label pilot study
Gustavo C. Leal ,
Igor D. Bandeira ,
Fernanda S. Correia-Melo ,
Manuela Telles ,
Rodrigo P. Mello ,
Flavia Vieira ,
Cassio S. Lima ,
Ana Paula Jesus-Nunes ,
Lívia N. F. Guerreiro-Costa ,
Roberta F. Marback ,
Ana Teresa Caliman-Fontes ,
Breno L. S. Marques ,
Marília L. O. Bezerra ,
Alberto L. Dias-Neto ,
Samantha S. Silva ,
Aline S. Sampaio ,
Gerard Sanacora ,
Gustavo Turecki ,
Colleen Loo ,
Acioly L. T. Lacerda ,
Lucas C. Quarantini
February 20 2020
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
<p class="first" id="d1538553e358">We aimed to analyze the efficacy and safety of
arketamine, the R(-)-enantiomer of
ketamine, for treatment-resistant depression (TRD) in humans. Open-label pilot trial,
seven subjects with TRD received a single intravenous infusion of arketamine (0.5 mg/kg);
primary outcome was change in Montgomery-Åsberg Depression Rating Scale (MADRS) 24 h
after. Mean MADRS dropped from 30.7 before infusion to 10.4 after one day, a mean
difference of 20.3 points [CI 95% 13.6-27.0; p < 0.001]; dissociation was nearly
absent.
Arketamine might produce fast-onset and sustained antidepressant effects in humans
with favorable safety profile, like previously reported with animals; further controlled-trials
are needed.
</p>